Catalent (CTLT) Chief Executive Alessandro Maselli said Monday that the company will continue to operate as a contract development and manufacturing organization, or CDMO, after its acquisition by Novo Nordisk's (NVO) controlling shareholder Novo Holdings.
In an open letter to customers Monday, Maselli said he would continue as CEO and president of Catalent as he sought to reassure customers, saying Catalent will continue to meet its existing commitments while protecting customers' proprietary production and ingredient information after the deal closes.
Novo Holdings announced plans to buy Catalent in February, with the deal valuing the target company at $63.50 per share.
The buyout is expected to close before the end of 2024, subject to regulatory and shareholder approvals and other customary conditions, the companies have said.
Price: 60.26, Change: -0.03, Percent Change: -0.05
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。